Prodrug Information
Prodrug General Information | Top | |||||
---|---|---|---|---|---|---|
Prodrug ID |
D6UA5D
|
|||||
Prodrug Name |
Nabumetone
|
|||||
Synonyms |
Relafen; 4-(6-methoxynaphthalen-2-yl)butan-2-one; Arthaxan; Nabumetona; Relifex; nabumeton; Listran; Relifen; 4-(6-Methoxy-2-naphthyl)-2-butanone; Consolan; Mebutan; Balmox; Relif; Dolsinal; Flambate; Unimetone; Prodac; Nabumetonum [INN-Latin]; Nabumetonum; Nabuser; 4-(6-Methoxy-2-naphthalenyl)-2-butanone; BRL 14777; BRL-14777; UNII-LW0TIW155Z; BRL14777; MLS000069541; 4-(2-Methoxynaphthalen-6-yl)butan-2-one; 2-Butanone, 4-(6-methoxy-2-naphthalenyl)-; BRN 2103472; LW0TIW155Z; SMR000058835; MFCD00079518; NCGC00016853-01; CAS-42924-53-8; Nabumetone (JP17/USP/INN)
Click to Show/Hide
|
|||||
Indication | Osteoarthritis [ICD-11: FA00-FA05; ICD-9: 715] | Approved | [1] | |||
Rheumatoid arthritis [ICD-11: FA20; ICD-9: 729] | Approved | [1] | ||||
Activation |
Prodrug |
Parent Drug |
||||
2D MOL 3D MOL | 2D MOL 3D MOL | |||||
(1) Bioconversion Enzyme:
CYP1A2
(EC 1.14)
|
[2] | |||||
Prodrug Strategy |
Classical prodrug strategy
[Bioprecursor prodrug]
|
|||||
Improved property |
Minimize side effect
|
[3] | ||||
Formula |
C15H16O2
|
|||||
Canonical SMILES |
CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC
|
|||||
InChI |
1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3
|
|||||
InChIKey |
BLXXJMDCKKHMKV-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 42924-53-8
|
|||||
PubChem Compound ID | ||||||
ChEBI ID |
CHEBI:7443
|
Parent Drug General Information | Top | |||||
---|---|---|---|---|---|---|
Parent Drug ID |
DI2ZS0
|
|||||
Parent Drug Name |
6-MNA
|
|||||
Synonyms |
6-Methoxynaphthalene-2-acetic acid; 2-(6-methoxynaphthalen-2-yl)acetic acid; 6-Methoxy-2-naphthylacetic acid; (6-methoxy-2-naphthyl)acetic acid; 6-methoxy Naphthalene Acetic Acid; 6-Methoxy-2-naphthaleneacetic acid; 6-MNAA; BRL 10720; (6-methoxynaphthalen-2-yl)acetic acid; Naproxen EP Impurity I; 2-NAPHTHALENEACETIC ACID, 6-METHOXY-; 2-(6-methoxy-2-naphthyl)acetic acid; 6-Metossi-2-naphtil acetico [Italian]; BRN 2371586; 6-methoxynaphth-2-ylacetic acid; CHEBI:35628; alpha-Demethylnaproxen; 6-MNA cpd; 6MNA; MCULE-6960041836; VZ30789; (6-methoxynaphthalen-2-yl)-acetic acid; KSC-419-062; (6-methoxy-naphthalen-2-yl)-acetic acid; 2-(6-methoxy-2-naphthalenyl)acetic acid
Click to Show/Hide
|
|||||
Formula |
C13H12O3
|
|||||
Canonical SMILES |
COC1=CC2=C(C=C1)C=C(C=C2)CC(=O)O
|
|||||
InChI |
1S/C13H12O3/c1-16-12-5-4-10-6-9(7-13(14)15)2-3-11(10)8-12/h2-6,8H,7H2,1H3,(H,14,15)
|
|||||
InChIKey |
PHJFLPMVEFKEPL-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 23981-47-7
|
|||||
PubChem Compound ID | ||||||
ChEBI ID |
CHEBI:35628
|
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2005 | |||||
REF 2 | Carbon-carbon bond cleavage in activation of the prodrug nabumetone. Drug Metab Dispos. 2014 May;42(5):828-38. | |||||
REF 3 | The unique pharmacologic profile of nabumetone. J Rheumatol Suppl. 1992 Nov;36:13-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.